Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Persistence with biologic treatments in psoriasis: A structured literature review of studies using administrative database and clinical registry data
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Dermatology and Venerology.ORCID iD: 0000-0001-7241-8471
2022 (English)In: Journal of Drugs in Dermatology, ISSN 1545-9616, Vol. 21, no 8, p. 881-889Article, review/survey (Refereed) Published
Abstract [en]

Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often estimated using data from administrative databases and clinical registries. Persistence rates calculated from these two data sources appear to be systematically different.

Objective: Review and compare persistence rates of psoriasis-indicated biologics reported in registry and database studies.

Methods: A structured literature search of studies published during 2009-2019 was performed in PubMed and American Academy of Dermatology records to identify research describing persistence with biologic treatments in psoriasis patients. English language retrospective or prospective persistence studies based on database or registry data, and reporting on at least two psoriasis-indicated biologics, of which at least one was ustekinumab, secukinumab, ixekizumab or guselkumab, were included. Single-arm studies, randomized control trials, systematic literature reviews, and studies presenting stratified results only were excluded.

Results: A total of 37 studies (22 registry- and 15 database-derived) comprising 76,000 patients were included. On average, drug persistence collected from registry studies was 18% higher than database studies.

Conclusion: The findings of this study may be used by practitioners to make meaningful comparisons between persistence data derived from registries and databases, and thereby improve clinical decision making.

Place, publisher, year, edition, pages
Journal of Drugs in Dermatology , 2022. Vol. 21, no 8, p. 881-889
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:umu:diva-218267DOI: 10.36849/JDD.6789R1ISI: 000847393500012PubMedID: 35946982Scopus ID: 2-s2.0-85136339956OAI: oai:DiVA.org:umu-218267DiVA, id: diva2:1820922
Available from: 2023-12-19 Created: 2023-12-19 Last updated: 2024-01-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopusPublishers' website

Authority records

Geale, Kirk

Search in DiVA

By author/editor
Geale, Kirk
By organisation
Dermatology and Venerology
Dermatology and Venereal Diseases

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf